Focused On-demand Library for Protein Daple

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9P219

UPID:

DAPLE_HUMAN

Alternative names:

Coiled-coil domain-containing protein 88C; Dvl-associating protein with a high frequency of leucine residues; Hook-related protein 2

Alternative UPACC:

Q9P219; Q69YK1; Q7L1M2; Q86SX7; Q8IYG8

Background:

Protein Daple, known for its alternative names such as Coiled-coil domain-containing protein 88C, plays a pivotal role in non-canonical Wnt signaling. It activates G-proteins, interacts with the Wnt receptor FZD7, and facilitates non-canonical Wnt responses, including RAC1 and PI3K-AKT signaling pathways. This protein's ability to promote apical constriction of cells underscores its significance in cellular processes.

Therapeutic significance:

Protein Daple's involvement in congenital hydrocephalus and spinocerebellar ataxia 40 highlights its potential as a therapeutic target. Understanding its role in these diseases could pave the way for innovative treatments, emphasizing the importance of research in this area.